RxDoctor Payments Data

David Simon, MD

Internal Medicine · Anaheim, CANPI 1922089135

Payments from drug & device makers

$1,139in general payments, 2019–2025

Across 75 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$265
  • Novo Nordisk$181
  • GSK$146
  • Pfizer$129
  • Lilly USA, LLC$105
  • Boehringer Ingelheim$96
  • plus $217 from 6 others

What the payments were for

  • Food & beverage$1,12899%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,139 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$32,813
Medicare patients
104
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$86,988
JardianceEmpagliflozin60$78,194
OzempicSemaglutide43$61,959
JanuviaSitagliptin Phosphate35$42,052
TrulicityDulaglutide17$20,465
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,168
Spiriva HandihalerTiotropium Bromide12$7,905
Atorvastatin Calcium532$5,518
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$5,172
Clonidine26$3,676
Metoprolol Succinate170$2,514
Colestipol Hcl15$2,369
SynthroidLevothyroxine Sodium25$2,291
Metformin Hcl188$2,250
Benazepril-HydrochlorothiazideBenazepril/Hydrochlorothiazide33$2,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$86,98890 claims
Boehringer IngelheimJardiance$96$78,19460 claims
Novo NordiskOzempic$181$61,95943 claims
MerckJanuvia$51$42,05235 claims
Lilly USA, LLCTrulicity$105$20,46517 claims
GSKTrelegy Ellipta$146$8,16813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →